Department of Health Services Research CAPHRI Care and Public Health Research Institute Maastricht University, The Netherlands
Division of Public Health, Epidemiology and Health Economics WHO Collaborating Centre for Public Health Aspects of Musculo-Skeletal Health and Aging, University of Liège, Belgium Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh.
J Manag Care Spec Pharm. 2020 Mar;26(3):334-335. doi: 10.18553/jmcp.2020.26.3.334.
No funding was involved in the writing of this letter. Outside of the submitted work, Hiligsmann has received research grants through institution from Amgen, Radius Health, UCB, and Teva/Theramex. Reginster has received research grants and/or consulting fees from Servier, Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed-Takeda, NPS, IBSA Genevrier, Theramex, UCB, Asahi Kasei, Endocyte, Merck Sharp and Dohme, Rottapharm, Teijin, Teva, Analis, NovoNordisk, Ebewee Pharma, Zodiac, Danone, Will Pharma, Meda, Bristol Myers Squibb, Pfizer, Organon, Therabel, Boehringer, Chiltern, and Galapagos. Silverman has received grant support from Amgen, Radius, and Lilly; consulting fees from Amgen and Radius; has served on scientific advisory boards for Lilly and Amgen; and has served on speakers bureaus for Amgen, Lilly, and Radius.
本信函的撰写未接受任何资金资助。除已提交的工作外，Hiligsmann 通过机构从安进（Amgen）、Radius Health、UCB 和梯瓦（Teva/Theramex）获得研究资助。Reginster 已从 Servier、诺华（Novartis）、Negma、礼来（Lilly）、惠氏（Wyeth）、安进（Amgen）、葛兰素史克（GlaxoSmithKline）、罗氏（Roche）、默克（Merckle）、奈科明（Nycomed-Takeda）、NPS、IBSA Genevrier、Theramex、UCB、旭化成（Asahi Kasei）、Endocyte、默克 Sharp & Dohme、Rotapharm、特瓦（Teva）、Analis、诺和诺德（NovoNordisk）、Ebewee Pharma、Zodiac、达能（Danone）、威凡（Will Pharma）、美达施（Meda）、百时美施贵宝（Bristol Myers Squibb）、辉瑞（Pfizer）、欧加农（Organon）、Therabel、勃林格殷格翰（Boehringer）、奇尔腾（Chiltern）和盖伦（Galapagos）获得研究资助和/或咨询费。Silverman 获得了安进、Radius 和礼来的资助支持；从安进和 Radius 获得咨询费；曾担任礼来和安进的科学顾问委员会成员；并担任过安进、礼来和 Radius 的演讲人局成员。
